Form D · Pharmaceuticals
Quest PharmaTech Inc.
Edmonton, A0 · CIK 0001657074
Offering snapshot reported Oct 29, 2015 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $1.5M Reported outside-investor minimum
- First sale
- Oct 13, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2015 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-250328
C$2,000,000 (Canadian Dollars) equating to approximately $1,500,000 (US Dollars)
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Oct 29, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bin Huang | Director |
| Ragupathy Madiyalakan | Director |
| Madi Madiyalakan | Executive |
| Ian Mc Connan | Director |
| Lorne Meikle | Director |
| Paul Van Damme | Director |
| Pierre Vermette | Executive |
| Thomas Woo | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8123 Roper Road Nw
Edmonton, A0, T6E 6S4
Edmonton, A0, T6E 6S4